News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BAC B.V. Affinity Ligand Licensed for Clinical and Commercial Scale-up of LFB Biotechnologies' Recombinant Factor VIIa


4/13/2010 10:24:24 AM

NAARDEN, Netherlands--(BUSINESS WIRE)--BAC BV, the leading provider of antibody-based affinity purification technology, has announced that it has extended its license agreement with LFB Biotechnologies (Les Ulis, France), to cover the use of BAC’s anti-Factor VIIa CaptureSelect® affinity ligand in the large-scale purification of recombinant human Factor VIIa (rhFVIIa). LFB Biotechnologies, a biopharmaceutical company working in the highly specialized field of plasma-derived medicinal and biotech products, began working with BAC in May 2008 to develop a custom-designed affinity ligand for the purification of the rhFVIIa product that it developed in partnership with GTC Biotherapeutics (Nasdaq:GTCB).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES